The ELEVATE Act of 2026 would amend the Securities Exchange Act of 1934 to change certain registration-statement requirements for issuers, with a particular focus on emerging growth companies. It would revise the contents required in registration statements so that emerging growth companies generally need provide only the two most recent fiscal years of financial information, rather than a longer historical period, in the specified filing context.
The bill also would allow any issuer to confidentially submit a draft registration statement to the Securities and Exchange Commission for nonpublic staff review before publicly filing it. Under the bill, the initial confidential submission and any amendments would still have to be publicly filed at least 10 days before the security is listed on a national securities exchange. The bill further states that the SEC could not be compelled to disclose information submitted or obtained under this process, and it would treat that information as confidential for purposes of federal disclosure law.
Impact
If enacted, the bill would amend federal securities law, specifically Section 12(b) of the Securities Exchange Act of 1934, by altering registration statement disclosure requirements and creating a statutory basis for confidential draft submissions to the SEC. It would affect issuers seeking to go public, especially emerging growth companies, and would give the SEC explicit authority to keep draft registration materials confidential under the bill’s terms.
Sentiment
No committee transcript or vote record is available, so there is no documented debate or recorded sentiment in the provided materials. Based on the bill’s sponsors and its structure, the measure appears to be framed as a pro-capital-formation and issuer-friendly securities modernization bill, but the available record does not show whether it is broadly supported or opposed in committee.
Contention
The main points of potential contention are likely to be the reduced disclosure burden for emerging growth companies and the expansion of confidential SEC review for all issuers. Supporters would likely view these changes as lowering costs, speeding the IPO process, and improving access to capital for smaller or newer companies. Critics could argue that limiting historical financial disclosure and increasing confidentiality may reduce transparency for investors and delay public scrutiny of offering materials.